Biotech Values

[dewophile]

In the open label fibrosis did correlate w fvc. The problem w including the very sick is they die before you get enough duration of drug to see effect I think that's why itmn also didn't allow these PTS in their ph 3. Shifting geRs since you seem very familiar w this space curious what you think of PLI they have an oral drug that acts in large part on Ctgf that may be entering the clinic also any other competitiors. I bought in for the anemia drug but like you think the really big money could be if the ipf drug succeeds. As for first line I'm ok w combos I bet we see docs start combos of the FDA drugs already on market and to be a realist second line is likely where fgen looks to go first unless the data is stellar in the current trial